[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]

Turkish Journal of Cancer
2006, Volume 36, Number 1, Page(s) 011-018
[ Summary ] [ Full Text ] [ PDF ]
The effect of EGFR overexpression in inoperable non-small cell lung cancer (NSCLC) patients receiving cisplatinvinorelbine combination
MAHMOUD A. SALAM1, TAMER ELNAHHAS1, HATEM A. AZIM2, SAMY ALSIRAFY1
1Department of Clinical Oncology, Cairo University Hospital, NCI, Cairo University, Cairo-Egypt
2Department of Medical Oncology, NCI, Cairo University, Cairo-Egypt

The epidermal growth factor receptor (EGFR; Her1, erb B1) is overexpressed in many tumors including NSCLC and has been associated with poorer outcome. We included 39 newly diagnosed patients with locally advanced and metastatic NSCLC in the period from January 2001 to April 2002. EGFR protein in serum was analyzed in all patients with a cut off value of 180 fmol/ml. All patients received cisplatinum (75 mg/m2) on day 1 and vinorelbine (25 mg/m2) on day 1 and day 8 every 3 weeks for a maximum of six cycles until progression or refusal of treatment. Sixteen (41.0%) showed a level below 180 fmol/ml (no overexpression) and were assigned to ARM 1 and 23 patients (59.0%) showed a level higher than the cut-off value (overexpression) and were assigned to ARM 2. The overall response rate to chemotherapy was 53.8%. Median time to disease progression was 3.5 months. The response rate was 62.5% for ARM 1 versus 47.8% for ARM 2 (p=0.31). Median time to disease progression was 7.8 months in ARM 1 versus 3.9 months in ARM 2 (p=0.039). The median survival was 15 months in ARM 1 versus 10 months in ARM 2 (p >0.05). Results showed that 59% of the cases showed overexpression for EGFR protein. This overexpression can be a poor prognostic factor in NSCLC and those cases can be candidates for newly developed targeted therapy. [Turk J Cancer 2006;36(1):11-18].

[ Summary ] [ Full Text ] [ PDF ]
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]